Annexon Submits First-Ever Targeted Therapy for Guillain-Barré Syndrome to European Regulators
核心洞察
Annexon has submitted a Marketing Authorization Application to the European Medicines Agency (搜索) for tanruprubart (搜索), potentially the first targeted fast-acting therapy for Guillain-Barré syndrome (搜索).
The submission is based on comprehensive Phase 3 data showing tanruprubart (搜索) rapidly stops neuroinflammation and enables faster, more complete patient recovery from this life-threatening disease.
Guillain-Barré syndrome (搜索) affects at least 150,000 people worldwide annually with no currently approved treatments, representing a significant unmet medical need.
Annexon, Inc. has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (搜索) for tanruprubart (搜索), marking a potential breakthrough in treating Guillain-Barré syndrome (搜索) (GBS), a rare neuroinflammatory disease that currently has no approved therapies.
The Brisbane, California-based biopharmaceutical company announced the regulatory submission on January 8, 2026, representing what could become the first targeted, fast-acting treatment for GBS and establish a new standard of care for this devastating condition.
Addressing Critical Unmet Medical Need
GBS affects at least 150,000 people worldwide each year, with no U.S. Food and Drug Administration (搜索) approved treatments currently available. The acute neuroinflammatory disease involves damage to peripheral nerves necessary for movement and breathing, often rapidly progressing to severe weakness or complete paralysis requiring intensive care.
"GBS is a sudden, debilitating disease that robs patients of their independence despite treatment with IVIg or plasma exchange, which require intensive, multi-day administration and provide incomplete benefit for many patients," said Hugh Willison, MBBS, PhD, professor emeritus of neurology at University of Glasgow.
The disease results in hospitalization of more than 22,000 people annually in the U.S. and Europe, with the long-term disease burden leading to a multi-billion-dollar annual economic cost to the U.S. healthcare system alone.
Breakthrough Mechanism of Action
Tanruprubart (搜索) represents a first-in-class targeted and rapid-acting agent designed to reduce inflammation and nerve damage by stopping C1q (搜索) activity in the peripheral and central nervous systems. The investigational antibody is designed to block classical complement (搜索)-driven inflammation at its source and has been observed in GBS to act almost immediately with a single infusion to stop early nerve damage.
"In the landmark Phase 3 study, tanruprubart (搜索) was shown to rapidly stop neuroinflammation, enabling GBS patients to recover faster and more completely from this sudden, life-threatening disease that has no approved disease modifying therapies," said Douglas Love, president and chief executive officer of Annexon.
Comprehensive Clinical Evidence Package
The MAA submission includes a comprehensive data package demonstrating rapid impact on markers of neuroinflammation and disease, with patients recovering faster and more completely on both functional and clinical disability outcome measures. The evidence is supported by significant improvement with treatment and favorable risk/benefit analysis shown in two randomized, placebo-controlled studies: proof-of-concept and pivotal Phase 3 studies conducted in Southeast Asia.
The submission also includes a robust generalizability package demonstrating classical complement (搜索) as a key driver of GBS regardless of geography, with tanruprubart (搜索) treatment outcomes applicable to Western patient populations. This package is supported by a large U.S. and Southeast Asian biomarker dataset, population pharmacokinetics analysis across multiple regions, and a Real-World Evidence study matching Phase 3 patients to IVIg- or plasma exchange-treated Western patients from a 2,000-patient, prospective GBS observational study.
Regulatory Recognition and Future Plans
Tanruprubart (搜索) has received both Fast Track and Orphan Drug designations from the FDA as well as orphan drug designation from the EMA for GBS treatment, indicating recognized need for better treatments.
Annexon continues to evaluate tanruprubart (搜索) in the ongoing open-label FORWARD study in the U.S. and Europe, designed to support a broad label across pediatric and adult patients and further expand the use of tanruprubart across geographies. A Biologics License Application submission to the FDA with data from the FORWARD study is planned in 2026.
"This submission is an important step on many fronts as we move closer to achieving our mission of helping millions of patients impacted by devastating neuroinflammatory diseases (搜索) live their best lives," Love added.
The potential approval of tanruprubart (搜索) would represent a significant advancement for the nearly 10 million people worldwide living with serious neuroinflammatory diseases (搜索), offering hope for a targeted therapy that could rapidly halt disease progression and improve patient outcomes.